Subscribe

What are you looking for?

Main Menu

明報新聞網

體重管理生科公司先為達生物遞表申上市 騰訊美團為股東

Future Wealths
Future Wealths
23 3 月, 2026
One Min Read
8 Views
0 Comments
內地研發先進體重管理療法的生物公司先為達生物，向港交所（0388）遞表申請上市，公司主要研發肥胖症及相關疾病的療法，聯席保薦人為摩根士丹利及中金。騰訊（0700）及美團（3690）均是為達生物主要股東。

原文: https://finance.mingpao.com/fin/instantf/20260323/1774275324541/%E9%AB%94%E9%87%8D%E7%AE%A1%E7%90%86%E7%94%9F%E7%A7%91%E5%85%AC%E5%8F%B8%E5%85%88%E7%82%BA%E9%81%94%E7%94%9F%E7%89%A9%E9%81%9E%E8%A1%A8%E7%94%B3%E4%B8%8A%E5%B8%82-%E9%A8%B0%E8%A8%8A%E7%BE%8E%E5%9C%98%E7%82%BA%E8%82%A1%E6%9D%B1%22%20target=%22blank

Last Update: 23 3 月, 2026

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept